May 19th 2023
According to interim phase 2 results, GEN-001 in combination with avelumab has a significant objective response rate in patients with gastric and gastroesophageal junction adenocarcinoma.
PD-L1 CPS Plays Role in Selecting Treatment for Gastric Cancer
December 9th 2022During a Targeted Oncology case-based roundtable event, Syma Iqbal, MD, discussed the addition of nivolumab to chemotherapy for patients with gastric/gastroesophageal junction cancer based on PD-L1 status. This is the second of 2 articles based on this event.
Read More
Managing Adverse Events of Nivolumab/Chemotherapy for Gastric/GEJ Cancers
November 18th 2022During a Targeted Oncology case-based roundtable event, Syma Iqbal, MD, discussed with participants their impressions of the CheckMate 649 chemoimmunotherapy regimen for patients with gastric/gastroesophageal junction cancers. This is the first of 2 articles based on this event.
Read More
Updated Results Support Efficacy of Trastuzumab Deruxtecan in Metastatic Gastric/GEJ Cancer
September 11th 2022New results from the DESTINY-Gastric02 study include responses, survival data for patients receiving trastuzumab deruxtecan for with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Read More
Doctors Debate: Is PD-L1 Testing Necessary Before Starting ICI Therapy in Gastroesophageal Cancer?
March 28th 2022During a debate at the Gastrointestinal Cancers Symposium, Florian Lordick, MD, argued that knowledge of PD-L1 expression level was needed before starting immune checkpoint inhibitor therapy. He was challenged by Aaron James Scott, MD, who argued that knowledge of PD-L1 is not necessary before initiating immune checkpoint inhibitor therapy.
Read More
Global Studies Evaluate Safety/Efficacy of TST001 for Locally Advanced or Metastatic Solid Tumors
March 25th 2022TST001 has shown to be safe in ongoing trials alone or in combination with chemotherapy and displayed encouraging anti-tumor activity signals in gastric cancer and other solid tumor patients expressing CLDN18.2.
Read More
Tweet Chat Recap: Janjigian Discusses Biomarkers to Consider for Patients With Gastric Cancer
March 24th 2022In an interview with Targeted Oncology following the tweet chat, Yelena Y. Janjigian, discussed the key takeaways from the discussion and highlighted the biomarkers and standard of care for the patient in this case.
Read More
First-Line Nivolumab/Chemotherapy Could Benefit Patients With Gastric/GEJ/Esophageal Cancers
March 6th 2022In an interview with Targeted Oncology, Ryan Sugarman, MD, discussed the CheckMate 649 trial and Q-TWiST results to provide a further understanding of survival and quality of life benefit of nivolumab plus chemo versus chemo alone.
Read More
DKN-01 Triplet Shows Encouraging Early Efficacy/Safety in Frontline Gastroesophageal Adenocarcinoma
March 1st 2022Findings show DKN-01, tislelizumab, and capecitabine/oxaliplatin (CAPOX) combination to be well tolerated and have encouraging clinical activity as frontline treatment of patients with advanced gastroesophageal adenocarcinoma.
Read More
Trastuzumab Deruxtecan Extends Overall Survival in HER2+ Advanced Gastric/GEJ Cancer
January 20th 2022Updated survival results from the phase 2 DESTINY-Gastric01 trial reveal the survival benefit of trastuzumab deruxtecan HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma.
Read More
Evorpacept Pairs Well With Anticancer Regimens Plus Chemotherapy to Elicit Responses in Solid Tumors
November 10th 2021The novel checkpoint inhibitor, evorpacept induced responses in patients with head and neck squamous cell carcinoma and gastric cancer when used in combination with anticancer therapy and chemotherapy in a phase 1b study.
Read More
Data from the phase 3 CheckMate-649 trial showed that the combination therapy of nivolumab and chemotherapy showed a sustained survival benefit in patients with advanced gastric, gastroesophageal junction (GEJ), or esophageal cancer, in contrast to the combination of nivolumab and ipilimumab.
Read More
Survival Benefit in Frontline Esophageal Squamous Cell Carcinoma Seen With Toripalimab/Chemo Combo
September 17th 2021In patients with advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 expression, the addition of toripalimab to platinum-based chemotherapy demonstrated significantly improved survival outcomes.
Read More
Limited Clinical Activity in Second-Line Gastric/GEJ Cancer Seen With Linagliptin/Atezolizumab Combo
September 16th 2021Limited responses as a second-line treatment for patients with locally advanced or metastatic gastric or gastroesophageal junction cancer were seen with Linagliptin plus atezolizumab.
Read More
Pembrolizumab Withdrawn From US Market as Option For Third-Line Gastric or GEJ Adenocarcinoma
July 6th 2021Pembrolizumab has been voluntarily withdrawn from the North American market as a treatment option for patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
Read More